Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

Morie Gertz, Evangelos Terpos, Angela Dispenzieri, Shaji K Kumar, Rupin A. Shah, Robert Orlowski, Efstathios Kastritis, Meletios A. Dimopoulos, Jatin Shah

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities.

Original languageEnglish (US)
Pages (from-to)1723-1726
Number of pages4
JournalLeukemia and Lymphoma
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Myelodysplastic Syndromes
Multiple Myeloma
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Therapeutics
Melphalan
Stem Cells
Transplants

Keywords

  • Acute leukemia
  • Hypomethylating agents
  • Lenalidomide
  • Multiple myeloma
  • Myelodysplasia
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. / Gertz, Morie; Terpos, Evangelos; Dispenzieri, Angela; Kumar, Shaji K; Shah, Rupin A.; Orlowski, Robert; Kastritis, Efstathios; Dimopoulos, Meletios A.; Shah, Jatin.

In: Leukemia and Lymphoma, Vol. 56, No. 6, 01.06.2015, p. 1723-1726.

Research output: Contribution to journalArticle

Gertz, Morie ; Terpos, Evangelos ; Dispenzieri, Angela ; Kumar, Shaji K ; Shah, Rupin A. ; Orlowski, Robert ; Kastritis, Efstathios ; Dimopoulos, Meletios A. ; Shah, Jatin. / Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 6. pp. 1723-1726.
@article{9e4ae5df48ed45988c4bd9d41bc28673,
title = "Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents",
abstract = "Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities.",
keywords = "Acute leukemia, Hypomethylating agents, Lenalidomide, Multiple myeloma, Myelodysplasia, Stem cell transplant",
author = "Morie Gertz and Evangelos Terpos and Angela Dispenzieri and Kumar, {Shaji K} and Shah, {Rupin A.} and Robert Orlowski and Efstathios Kastritis and Dimopoulos, {Meletios A.} and Jatin Shah",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/10428194.2014.970543",
language = "English (US)",
volume = "56",
pages = "1723--1726",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

AU - Gertz, Morie

AU - Terpos, Evangelos

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

AU - Shah, Rupin A.

AU - Orlowski, Robert

AU - Kastritis, Efstathios

AU - Dimopoulos, Meletios A.

AU - Shah, Jatin

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities.

AB - Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities.

KW - Acute leukemia

KW - Hypomethylating agents

KW - Lenalidomide

KW - Multiple myeloma

KW - Myelodysplasia

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84932145803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932145803&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.970543

DO - 10.3109/10428194.2014.970543

M3 - Article

C2 - 25284489

AN - SCOPUS:84932145803

VL - 56

SP - 1723

EP - 1726

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -